Klas Bergenheim

1.1k total citations
50 papers, 851 citations indexed

About

Klas Bergenheim is a scholar working on Endocrinology, Diabetes and Metabolism, Economics and Econometrics and Molecular Biology. According to data from OpenAlex, Klas Bergenheim has authored 50 papers receiving a total of 851 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Economics and Econometrics and 9 papers in Molecular Biology. Recurrent topics in Klas Bergenheim's work include Diabetes Treatment and Management (33 papers), Diabetes Management and Research (25 papers) and Health Systems, Economic Evaluations, Quality of Life (10 papers). Klas Bergenheim is often cited by papers focused on Diabetes Treatment and Management (33 papers), Diabetes Management and Research (25 papers) and Health Systems, Economic Evaluations, Quality of Life (10 papers). Klas Bergenheim collaborates with scholars based in Sweden, United Kingdom and United States. Klas Bergenheim's co-authors include Phil McEwan, Marc Evans, Hayley Bennett, P McEwan, John R. Peters, Oliver Darlington, Craig J. Currie, John J.V. McMurray, Martin Henriksson and Ola Granström and has published in prestigious journals such as PLoS ONE, Alimentary Pharmacology & Therapeutics and Clinical Journal of the American Society of Nephrology.

In The Last Decade

Klas Bergenheim

48 papers receiving 833 citations

Peers

Countries citing papers authored by Klas Bergenheim

Since Specialization

Citations

This map shows the geographic impact of Klas Bergenheim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klas Bergenheim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klas Bergenheim more than expected).

Fields of papers citing papers by Klas Bergenheim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klas Bergenheim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klas Bergenheim. The network helps show where Klas Bergenheim may publish in the future.

Co-authorship network of co-authors of Klas Bergenheim

This figure shows the co-authorship network connecting the top 25 collaborators of Klas Bergenheim. A scholar is included among the top collaborators of Klas Bergenheim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klas Bergenheim. Klas Bergenheim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts 2022 ·Diabetes Therapy ·(unknown), Klas Bergenheim, Juan José García Sánchez, (unknown), Andrew Briggs, Richard F. Pollock	0
2	PCV45 Cost-Effectiveness of Dapagliflozin Versus Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction 2020 ·Value in Health ·P McEwan, Oliver Darlington, Klas Bergenheim, (unknown)	2
3	Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF 2020 ·European Journal of Heart Failure ·Phil McEwan, Oliver Darlington, John J.V. McMurray, Pardeep S. Jhund, Kieran F. Docherty, Michael Böhm, Mark C. Petrie, Klas Bergenheim, Lei Qin	96
4	Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial 2017 ·Diabetes Research and Clinical Practice ·Andrew Briggs, Deepak L. Bhatt, Benjamin M. Scirica, Itamar Raz, Karissa Johnston, Shelagh M. Szabo, Klas Bergenheim, Jayanti Mukherjee, Boaz Hirshberg, Ofri Mosenzon	25
5	A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus 2016 ·PharmacoEconomics ·Martin Henriksson, (unknown), (unknown), Klas Bergenheim, Elisabeth Sörstadius, Michael Willis	29
6	A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus 2015 ·Value in Health ·Martin Henriksson, (unknown), (unknown), Elisabeth Sörstadius, Klas Bergenheim, Michael Willis	13
7	Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model 2015 ·Cost Effectiveness and Resource Allocation ·(unknown), Thomas Ward, Hayley Bennett, Klas Bergenheim	34
8	Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK 2014 ·PharmacoEconomics ·Phil McEwan, Hayley Bennett, Thomas Ward, Klas Bergenheim	18
9	Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK 2014 ·Diabetes Therapy ·Hayley Bennett, Phil McEwan, Klas Bergenheim, Jason Gordon	9
10	Comparing the Event Prediction Capability of the Ukpds68 and Hong Kong Diabetes Risk Equations within A Type 2 Diabetes Simulation Model 2014 ·Value in Health ·Phil McEwan, Tom Ward, Hayley Bennett, Klas Bergenheim	1
11	Comparing the Use of Patient-Level Data to An Average Patient Profile Within a Type 2 Diabetes Simulation Model 2014 ·Value in Health ·P McEwan, Hayley Bennett, Thomas Ward, Klas Bergenheim	1
12	Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands 2013 ·Value in Health ·(unknown), (unknown), Klas Bergenheim, Phil McEwan, R. Townsend, (unknown)	1
13	Cost of Achieving Relevant Composite Endpoint of HbA1c<7%, No Hypoglycaemia and Weight Loss of ≥3% in a 52 Week Post-Hoc Analysis of Dapagliflozin Versus Glipizide 2013 ·Value in Health ·Klas Bergenheim, Susan Grandy, Gail Wygant	1
14	The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus Glipizide in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales 2013 ·Value in Health ·M. Charokopou, P McEwan, Steven Lister, (unknown), Klas Bergenheim, Keith Tolley, (unknown)	2
15	Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany 2012 ·Clinical Drug Investigation ·(unknown), Klas Bergenheim, I Duprat-Lomon, Phil McEwan	37
16	PDB53 Cost-Effectiveness of Saxagliptin (Onglyza®) in Type 2 Diabetes in South Africa 2012 ·Value in Health ·A. Juarez-Garcia, (unknown), (unknown), Klas Bergenheim, B.M.K. Donato	1
17	Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden 2011 ·Primary care diabetes ·Ola Granström, Klas Bergenheim, Phil McEwan, Karin Sennfält, Martin Henriksson	39
18	Assessing the Relationship between Computational Speed and Precision 2010 ·PharmacoEconomics ·Phil McEwan, Klas Bergenheim, Yong Yuan, (unknown), Jason Gordon	23
19	Äldreomsorgens finansiering - Varför äldrevårdsförsäkring? 2000 ·Lund University Publications (Lund University) ·Lars Söderström, Klas Bergenheim, Martin Karlsson, (unknown)	1
20	The Market for Pharmaceuticals 1998 ·PubMed ·Klas Bergenheim, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact